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Elección del tratamiento antibiótico en la 
infección invasiva aguda por Pseudomonas 
aeruginosa: Guía de la Sociedad Española de 
Quimioterapia
RESUMEN
Pseudomonas aeruginosa se caracteriza por una notable resis-
tencia intrínseca a los antibióticos mediada fundamentalmente por 
la expresión de β-lactamasas cromosómicas inducibles y la produc-
ción constitutiva o inducible de bombas de expulsión. Además de 
esta resistencia intrínseca, P. aeruginosa posee una extraordinaria 
capacidad para desarrollar resistencia a prácticamente todos los an-
timicrobianos disponibles a través de la selección de mutaciones. El 
aumento progresivo de la resistencia en P. aeruginosa ha llevado a 
la aparición de cepas que, de acuerdo con el grado de resistencia 
frente a los antibióticos habituales, se han definido como multirre-
sistentes, extensamente resistentes y panresistentes. Estas cepas se 
están diseminando mundialmente, complicando progresivamente el 
tratamiento de las infecciones por P. aeruginosa. En este escenario, 
el objetivo de las presentes recomendaciones es la revisión y puesta 
al día de la evidencia publicada para el tratamiento de pacientes con 
infección aguda, invasiva y grave por P. aeruginosa. Con este fin, se 
han revisado los mecanismos de resistencia intrínseca, factores que 
favorecen el desarrollo de resistencia durante la exposición a anti-
bióticos, prevalencia de la resistencia en España, antibióticos clásicos 
así como los de reciente introducción activos frente a P. aerugino-
sa, principios farmacodinámicos predictores de eficacia, experien-
cia clínica con tratamientos en monoterapia o terapia combinada y 
principios del tratamiento antibiótico para elaborar por un panel de 
expertos recomendaciones para el tratamiento empírico o dirigido 
de infecciones invasivas por P. aeruginosa.
Palabras clave: Pseudomonas aeruginosa, tratamiento, recomendaciones
ABSTRACT
Pseudomonas aeruginosa is characterized by a notable in-
trinsic resistance to antibiotics, mainly mediated by the expres-
sion of inducible chromosomic β-lactamases and the production 
of constitutive or inducible efflux pumps. Apart from this intrin-
sic resistance, P. aeruginosa possess an extraordinary ability to 
develop resistance to nearly all available antimicrobials through 
selection of mutations. The progressive increase in resistance 
rates in P. aeruginosa has led to the emergence of strains which, 
based on their degree of resistance to common antibiotics, 
have been defined as multidrug resistant, extended-resistant 
and panresistant strains. These strains are increasingly dissem-
inated worldwide, progressively complicating the treatment of 
P. aeruginosa infections. In this scenario, the objective of the 
present guidelines was to review and update published evidence 
for the treatment of patients with acute, invasive and severe 
infections caused by P. aeruginosa. To this end, mechanisms of 
intrinsic resistance, factors favoring development of resistance 
during antibiotic exposure, prevalence of resistance in Spain, 
classical and recently appeared new antibiotics active against 
P. aeruginosa, pharmacodynamic principles predicting efficacy, 
clinical experience with monotherapy and combination therapy, 
and principles for antibiotic treatment were reviewed to elabo-
rate recommendations by the panel of experts for empirical and 
directed treatment of P. aeruginosa invasive infections.
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venous catheter infection, burn wound infection, and urinary 
tract infection (pyelonephritis or prostatitis) in patients with 
vesical catheters. In all these circumstances, the severity of the 
infection and the risk of resistance in the infecting strain and 
of the empirical treatment resulting inadequate or generating 
higher degree of resistance, make important the knowledge 
of criteria guiding most appropriate treatment selection. The 
objective of the present guidelines is the treatment of this 
group of patients with acute, invasive, and usually severe in-
fections by P. aeruginosa. In the third group, chronic infections 
are included. Usually, isolates of P. aeruginosa from patients 
with cystic fibrosis produce an extracellular polysaccharide, 
alginate, conferring mucoid-type colonies. The same pheno-
type could be observed in bronchial infections in patients with 
bronchiectasis, advanced COPD (GOLD IV) or panbronchiolitis. 
These strains are usually less virulent and rarely produce bac-
teremia or extend beyond the lung. However, growth within 
biofilms makes difficult its eradication, and in advanced stages 
it is not possible with current treatments. 
The present document does not address the treatment 
of chronic infections observed in patients with cystic fibrosis 
or bronchiectasis since it was subject of two recently pub-
lished consensus [19,20]. We have reviewed the mechanisms 
of intrinsic and acquired resistance in P. aeruginosa, and their 
prevalence in Spain, to review afterwards the principles of 
treatment, basis for the further analysis of the main antibiotics 
with activity against P. aeruginosa. Lastly, recommendations 
for empirical and directed treatments are formulated. 
MECHANISMS OF INTRINSIC RESISTANCE IN  
P. aeruginosa AND RESISTANCE DEVELOPMENT 
DURING TREATMENT
P. aeruginosa is characterized by its notable intrinsic re-
sistance to antibiotics, mainly determined by the expression of 
inducible chromosomic AmpC β-lactamase and the produc-
tion of constitutive (MexAΒ-OprM) or inducible (MexXY) efflux 
pumps [21]. The expression of inducible AmpC is determinant 
in the natural resistance of P. aeruginosa to most penicillins 
and cephalosporins [22]. Besides, the constitutive expression 
of MexAΒ-OprM contributes to the reduced susceptibility of 
P. aeruginosa to all β-lactams (except imipenem) and fluoro-
quinolones [23]. In addition, the inducible expression of MexXY 
has a major role in the lower basal activity and adaptive (in-
ducible) resistance to aminoglycosides in P. aeruginosa [24]. 
Similarly, the inducible expression of operon arnBCADTEF, 
responsible for the addition of a 4-aminoarabinose residual to 
lipid A of the lipopolysaccharide, is critical for the development 
of inducible/adaptive resistance to polymyxins [25].
Apart from its notable intrinsic resistance, P. aerugi-
nosa possess an extraordinary ability to develop resistance 
to nearly all available antimicrobials, through the selection 
of mutations in a complex network of genes implicated in 
resistance and their regulation [21,26]. This fact has major 
consequences for the efficacy of treatments for P. aerugi-
nosa infections, mainly among critical patients at the ICU or 
Pseudomonas aeruginosa is not part of normal microbiota 
in healthy humans [1]. Significant and/or prolonged coloniza-
tion by P. aeruginosa occurs following loss of resistance to col-
onization due to changes in the composition of normal micro-
biota as consequence of antibiotic treatment and/or pre-exist-
ence of severe disease. Clinical and experimental observations 
indicate that, in both cases, colonization occurs within the first 
3-5 days of exposure to an environment with high exposure 
pressure, as in hospitals, mainly in Intensive Care Units (ICUs). 
In the 2016 ENVIN study, P. aeruginosa was the second most 
frequent isolated microorganism, just behind Escherichia coli, 
as cause of nosocomial infections in ICUs, and the third most 
frequent (after E. coli and Staphylococcus aureus) in commu-
nity-acquired infections requiring ICU admission. Mortality of 
bacteremia by P. aeruginosa is 20-39% [2-11], values similar 
to or greater than those for bacteremia by S. aureus and can-
didemia episodes. In ventilator associated pneumonia (VAP), 
mortality is even higher, reaching 44% [12,13].
The progressive increase in resistance rates in P. aerugino-
sa has led to the emergence  of strains which, based on their 
degree of resistance to common antibiotics, have been defined 
as multidrug resistant (MDR), extended-drug-resistant (XDR) 
and pan-drug-resistant (PDR) strains [14]. However, two new 
antibiotics active against P. aeruginosa have been introduced 
in the therapeutic armamentarium recently: 1) a new cephalo-
sporin, ceftolozane, associated with tazobactam, active against 
most of the strains resistant to the remaining β-lactams 
[15,16], and 2) ceftazidime associated with a new β-lactamase 
inhibitor, avibactam, able to block AmpC β-lactamases, includ-
ing those produced by P. aeruginosa [17,18]. Selection of the 
most appropriate antibiotic, dose, and route of administration, 
as well as potential association with other antibiotics, are criti-
cal decisions to obtain optimal clinical efficacy with the lowest 
risk of resistance increase and development of toxicity.
From the clinical point of view, infections caused by P. 
aeruginosa can be classified as: 1) acute superficial, nonin-
vasive, infections in immunocompetent patients, 2) acute in-
vasive infections in patients with significant comorbidities or 
immunodepression, and 3) chronic infections.  The first group 
includes the following entities: external otitis (swimmer’s ear), 
perichondritis, queratitis associated with the use of contact 
lens, hydromassage-associated folliculitis, paronychia (green 
nail syndrome), palmoplantar hidradenitis, foot bones osteo-
myelitis (secondary to puncture wounds by objects penetrat-
ing sport shoes), and interdigital intertrigo. In all these cases, 
the infection that follows the exposure to a high P. aerugino-
sa inocula could be self-limited or respond to topical or oral 
ciprofloxacin treatment, and only exceptionally could pose 
problems in relation to the presence or development of resist-
ance. The second group includes, among others, bacteremia, 
nosocomial pneumonia or VAP, endocarditis in parenteral 
drug users, pacemaker infections, necrotizing enterocolitis in 
the neutropenic patient, post-surgical meningitis, cerebro-
spinal fluid shunt infection, necrotizing fasciitis, gangrenous 
ecthyma, tertiary peritonitis or peritonitis associated with am-
bulatory peritoneal dialysis, malignant external otitis, central 
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P. aeruginosa, is the selection of mutants with constitutive 
hyperproduction (derepression) of inducible AmpC chro-
mosomic cephalosporinase [30]. Although AmpC derepres-
sion also increases MIC of ceftolozane-tazobactam, clinical 
resistance to this new combination requires an additional 
structural modification of AmpC, thus explaining the lower 
development of resistance [31]. The new combination of cef-
tazidime with the β-lactamase inhibitor avibactam, equally 
preserves activity against AmpC hyperproducer strains [32]. 
Among the great number of mutational resistance mecha-
nisms stand out the repression or inactivation of the OprD 
porine which, together with the inducible expression of 
AmpC, confers resistance to imipenem and reduced suscep-
tibility to meropenem [22]. Frequently, inactivation of OprD 
also synergically acts with derepression of AmpC, confering 
resistance to all available β-lactams except ceftolozane/ta-
zobactam [33] and ceftazidime/avibactam [32]. Finally, the 
hyperexpression of any of the multiple efflux pumps, mainly 
MexAΒ-OprM and MexXY-OprM and to a lesser entent Mex-
EF-OprN and MexCD-OprJ, significantly contributes to the 
resistance phenotypes [23]. MexAΒ-OprM is the efflux pump 
presenting the larger substrate profile. Its constitutive ex-
pression plays an important role in intrinsic resistance and its 
hyperexpression by chromosomic mutations affects all clas-
sical β-lactams (except imipenem) and fluoroquinolones. Hy-
perexpression of MexAΒ-OprM plus OprD inactivation is one 
those with chronic infections where the problem is magnified 
due to the high frequency of hypermutator strains, which 
present a spontaneous mutation rate up to 1000 times high-
er than normal [27]. The rate of spontaneous mutation for 
development of resistance usually ranges from 10-6 (1 mu-
tant per million bacteria) to 10-8 (1 mutant per 100 millions) 
for most antibiotics. Therefore, in those infections linked to 
high bacterial load (as respiratory infections) the probabil-
ity of resistance development is elevated for most classical 
antipseudomonal compounds, even for strains with normal 
rate of spontaneous mutation (non hypermutator strains). 
In fact, for most antipseudomonals mutant prevention con-
centrations (MPCs) [28] are frequently above concentrations 
achieved by systemic administration; colistin and ceftolo-
zane/tazobactam being among the few exceptions [29]. Table 
1 summarizes the characteristics of resistance development 
for the main antipseudomonals, including: a) main mech-
anisms of resistance developed through exposure to each 
antibiotic, b) the relatively frequency of spontaneous oc-
currence, c) the baseline minimal inhibitory concentrations 
(MICs) and MPCs, and d) development of cross-resistance to 
other antipseudomonals. 
The main mechanism of development of resistance to 
penicillins (ticarcillin, piperacillin, piperacillin-tazobactam) 









Primary R MEC Secondary R MEC
PIP/TZ +++ +++ ++ - ++ - + -/+ - - - 2 >32 ↑ AmpC ↑ MexAB
CAZ +++ +++ ++ -/+ ++ - + -/+ - - - 1 >32 ↑ AmpC ↑ MexAB
FEP ++ ++ +++ -/+ +++ - ++ + + - - 1 >32 ↑ MexAB/XY ↑ AmpC
TOL/TZ -/+ + + + -/+ - -/+ - - - - 0.5 2 ↑ AmpC+mut AmpC PBP3
ATM ++ ++ +++ -/+ +++ - ++ + - - - 4 >32 ↑ MexAB/XY ↑ AmpC
IMP -/+ -/+ -/+ - -/+ +++ ++ -/+ - - - 1 >32 OprD MexST (↑ MexEF ↓ OprD)
MER + + + - + ++ ++ + - - - 0.5 8 OprD ↑ MexAB, PBP3
FQb + + ++ - ++ -/+ + +++ + - - 0.12 2 QRDR ↑ MexAB/XY/CD/EF
AMGc - - + - - - - + ++ - - 1 8 ↑ MexXY FusA
COL - - -/+ - - -/+ -/+ -/+ + - 0.5 2 pmrAB/phoPQ parRS
FOS - - - - - - - - - - ++++ 64 >1,024 GlpT
Table 1  Activity and frequency of individual and cross-resistance resistance development for the different 
antipseudomonals, according to mechanisms implicated
PIP-TZ: piperacillin-tazobactam; CAZ: ceftazidime; FEP: cefepime; TOL-TZ: ceftolozane-tazobactam; ATM: aztreonam; IMP: imipenem; MER: meropenem; FQ: Fluoroquinolones; 
AMG: aminoglycosides; COL: colistin; FOS: fosfomycin. MIC: minimum inhibitory concentration. MPC: mutant prevention concentration (concentration preventing selection of 
resistant mutants). R MEC: resistance mechanism 
aFrequency of spontaneous development of clinical resistance (EUCAST resistance breakpoints) to antibiotics in columns by exposure to antibiotics in rows. (++++) Extremely 
elevated resistance development, (+++) Very elevated resistance development, (++) Elevated resistance development, (+) Moderate resistance development, (-/+) Low or impro-
bable resistance development, (-) Non expected resistance development. Data shown in the Table refer to wild-type strains without acquired mechanisms of resistance, using as 
reference strain PAO1 (28;236; A. Oliver data non published). bFQ resistance development: levofloxacin > ciprofloxacin (pumps hyperexpression). Data shown in the Table refer to 
ciprofloxacin. cResistance development aminoglycosides: gentamicin > amikacin > tobramycin. Data shown in the Table refer to tobramycin.
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2 shows the estimated prevalence and resistance mechanisms 
in P. aeruginosa that could be expected in Spanish hospitals. 
Overall, resistance rates are over 20% for most antipseu-
domonal antibiotics, including penicillins (piperacillin, piper-
acillin-tazobactam), cephalosporins (ceftazidime, cefepime), 
monobactams (aztreonam), carbapenems (imipenem, 
meropenem), fluoroquinolones (ciprofloxacin, levofloxacin) 
and aminoglycosides (gentamicin and tobramycin). Among 
the available antipseudomonal antibiotics, only colistin, 
amikacin and the recently introduced combination ceftolo-
zane-tazobactam exhibit an activity close to 95%. The prev-
alence of MDR strains is already above 30% worldwide, in-
cluding Spanish hospitals; approximately half of MDR strains 
would be also XDR [9]. The increasing prevalence of MDR/
XDR phenotypes results from the combination of the extraor-
dinary ability of P. aeruginosa to develop resistance against 
nearly all available antimicrobials through selection of chro-
mosomal mutations, together with the increasing frequency 
of exogenous resistance determinants, generally localized in 
integrons codified in transferable genetic elements (plasmids 
or transposons) [21]. Among these determinants, due to its 
clinical importance, the genes of β-lactamases with higher 
hydrolytic profile, class B carbapenemases (metallo-β-lacta-
mases, MBLs) and extended-spectrum β-lactamases (ESBLs), 
usually associated with determinants of aminoglycoside re-
sistance should be highlighted [36]. No 
doubt that intra-hospital dissemination, 
originating epidemic/endemic situations 
of MDR/XDR strains, plays an important 
role in the increasing magnitude of this 
problem. Even more important if posible is 
the alarming evidence of epidemic MDR/
XDR strains widely disseminated world-
wide, the so-called high-risk clones, main-
ly ST111, ST175 and ST235 [37]. A recent 
Spanish multicenter study (2015) showed 
that the most prevalent clone was by far 
ST175, being responsible for 68% cases 
of XDR P. aeruginosa in our country [38]. 
This study also showed that 20% of XDR 
strains were carbapenemase-producers 
(mainly VIM-type MBLs), while in the re-
maining 80% β-lactam resistance was me-
diated by chromosomal mutations (OprD 
inactivation + AmpC hyperproduction). It 
should be highlighted that although all 
XDR strains were resistant to all classical 
antipseudomonal β-lactams, only those 
carbapenemase-producing strains were 
highly resistant (MIC > 8 mg/L) to ceftolo-
zane-tazobactam. In fact, 68% of XDR 
strains were susceptible to this combina-
tion, although in many cases MICs were 
close to EUCAST and CLSI breakpoints (4 
mg/L) [38].  
Table 2  Prevalence and primary resistance mechanisms expected 
in P. aeruginosa in Spain.
PIP-TZ: piperacillin-tazobactam; CAZ: ceftazidime; FEP: cefepime; TOL-TZ: ceftolozane-tazobactam; ATM: 
aztreonam; IMP: imipenem; MER: meropenem; CIP: ciprofloxacin; TOB: tobramycin; AMK: amikacin; COL: 
colistin
aPrevalence of primary resistance expected in Spain, according to 2017 EUCAST breakpoints. When there is 
an intermediate susceptibility category, prevalence of non-susceptible strains (I+R) is shown and prevalence 
of resistant strains are in parenthesis. Data estimated using available information from EARS-Net (https://
ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/ears-net), mul-
ticenter studies (29;33;101;237) and microbiology department in several Spanish hospitals (H. Son Espases, 
Palma de Mallorca; H. Clinic, Barcelona; H. A Coruña, A Coruña). 
bRelative frequency of resistance mechanisms: +++ (20-30%), ++ (5-20%), + (1-5%), -/+ (<1%).
Antimicrobiala % I+R (R)a In order of frequency implicated mechanisms of resistanceb
PIP-TZ 20-30 ↑AmpC (++), ↑MexAB (+), MBL (+), OXAs and other ESBL (+)  
CAZ 20-30 ↑AmpC (++), ↑ MexAB (+), MBL (+), OXAs  and other ESBL (+)  
FEP 20-30 ↑MexAB/XY (++), ↑AmpC (++), MBL (+), OXAs  and other ESBL (+) 
TOL-TZ 1-5 MBL (+), OXAs and other ESBL (+) ↑AmpC+mut AmpC (-/+)
ATM >50 (20-30) ↑MexAB/XY (+++) ↑AmpC (++), OXAs and other ESBL (+)
IMP 20-30 (20-30) OprD (+++), MBL (+)
MER 20-30 (5-20) OprD (+++), ↑MexAB (++), MBL (+)
CIP 30-50 QRDR (+++), ↑MexAB/XY (++), ↑MexCD/EF (+)
TOB 20-30 Modified enzyme AMG (++) ↑MexXY (+)
AMK 5-20 (1-5) ↑MexXY (++),modified  enzyme AMG (+)
COL 1-2 pmrAB/phoPQ/parRS (-/+)
of the most frequent causes of clinical resistance to merope-
nem [34]. The expression of inducible MexXY plays an impor-
tant role in the intrinsic resistance to aminoglycosides, and 
its mutational hyperexpression in the acquired resistance to 
cefepime. Hyperexpression of MexEF-OprN and MexCD-OprJ 
is less frequent and mainly affects quinolones. However, 
mutations (mexT/mexS) leading to hyperexpression of Mex-
EF-OprN also confer decreased susceptibility to carbapenems 
through repression of oprD. Quinolone resistance is fre-
quently produced by mutations in topoisomerases including 
ADN gyrase (GyrA/GyrB) and type IV topoisomerases (ParC/
ParE). Lastly, development of resistance to polymyxins gener-
ally implies the modification of lipopolysaccharide mediated 
by mutations in the two-component systems involving Pmr-
AB, PhoPQ or ParRS [35]. Interactions between all these mu-
tations are complex, but it should be taken into account that 
in many cases the selection of a first mutation facilitates the 
subsequent selection of others, frequently resulting in MDR/
XDR phenotypes close to panresistance. 
PREVALENCE AND MECHANISMS OF PRIMARY 
RESISTANCE IN SPAIN
Although there are local important differences that 
should be analyzed and considered at each institution, table 
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side, and on the other, to relatively compensate the increased 
Vd and renal clearance in early phases of sepsis. 
Several studies performed in patients with P. aeruginosa 
infections analyzed the potential advantages of maintain-
ing serum β-lactam concentrations over MIC values for the 
maximum possible time through iv continuous or extended 
infusion administration. In a retrospective study including 87 
patients with bacteremia and/or pneumonia by P. aerugino-
sa, the extended infusion of cefepime (MIC50=4 mg/L) signifi-
cantly decrease mortality and days in the ICU compared with 
the standard intermittent administration [47]. In other study, 
piperacillin-tazobactam was administered as intermittent dos-
es or 4-hour extended infusion in the treatment of 194 pa-
tients with infections by P. aeruginosa [48]. For the extended 
infusion, doses were lower than those used for intermittent 
administration; however, both mortality was lower and mean 
hospital stay was shorter in the group of patients receiving ex-
tended infusion. The difference was significant only in the sub-
group of more severe patients (APACHE II ≥17) [48]. In cystic 
fibrosis patients with acute exacerbations of P. aeruginosa in-
fection, extended or continuous infusion of a β-lactam (gen-
erally ceftazidime) has shown to be better than intermittent 
dose administration, with respect to improvement of FEV1, 
forced vital capacity and extension of exacerbation-free inter-
vals [49]. The potential greater efficacy of continuous infusion 
has also been shown in Montecarlo simulations with patients 
treated with meropenem [50] or piperacillin-tazobactam [51] 
and in one case of carbapenem-resistant P. aeruginosa infec-
tion well controlled by 12g of meropenem extended infusion 
[52]. In rabbit models of infectious endocarditis caused by P. 
aeruginosa, maintained ceftazidime concentrations 4-5 times 
over the MIC provided optimal clinical efficacy [53,54]. In vitro 
models of P. aeruginosa infection also indicate that continu-
ous infusion is the most efficient administration for β-lactams 
[55-57].
In most clinical studies [58-66] but not in all [67-69], 
continuous or extended infusion of piperacillin-tazobactam, 
cefepime, ceftazidime or meropenem, for the treatment of 
infections by Gram-negative  bacilli (including P. aerugino-
sa) was more efficacious than intermittent administration 
with respect to the one or more following parameters: clinical 
cure rate, microbiological eradication, days with fever, length 
of ICU or hospital stay and decrease in severity (measured by 
APACHE II) and/or mortality. Negative or non-conclusive re-
sults in some studies might be explained by one or more of 
these facts: 1) the infecting microorganism was highly suscep-
tible to the antibiotic used (very low MIC) and the antibiotic 
administration as intermittent doses was enough to maintain 
a serum concentration over the MIC for most of the dosing 
interval [67], 2) patients were not critically ill and/or did not 
suffer a severe infection [69], 3) the dose used for intermit-
tent administration was frequently higher than the dose used 
for continuous infusion [63,69], 4) a significant number of pa-
tients was treated with a concomitant antibiotic (aminoglyco-
side or fluoroquinolone) [69], and 5) other factors that might 
have attenuated potential advantages of continuous infusion 
PRINCIPLES FOR THE TREATMENT OF INFECTIONS 
CAUSED BY P. aeruginosa
Principles guiding election of antibiotic treatment, wheth-
er empirical or directed treatment, in case of suspected or con-
firmed P. aeruginosa infections, are those also applying to any 
severe infection, but with some peculiarities as follows:  
1) MIC of main antibiotics active against P. aerug-
inosa. The breakpoint used to categorize P. aeruginosa as 
resistant to one β-lactam or aminoglycoside is from 2-times 
(piperacillin-tazobactam, imipenem, tobramycin, gentamicin) 
to 8-times (ceftazidime, cefepime) higher than the one used 
to consider resistant an enterobacteria. Against most clinical 
isolates of P. aeruginosa susceptible to β-lactams, the MIC of 
an antibiotic is usually at or close to its breakpoint value (2-
8 mg/L). For this reason, high doses of β-lactams are recom-
mended, even if the strain has been categorized as susceptible 
in in vitro susceptibility tests.
Clinical and/or bacteriological efficacy of β-lactams is re-
lated with the time of exposure of the microorganism to the 
antibiotic or the percentage of time that the free fraction of 
the antibiotic exceeds the MIC (% fT>CMI). In the treatment 
of infections by Gram-negative bacilli, including P. aeruginosa, 
ceftazidime and cefepime exhibits bactericidal effect (reduc-
tion of 2-3 log10 CFU) when serum concentrations exceed the 
MIC for more than 60% of the dosing interval [39]. Clinical 
cure, especially in severe infections, has been related with ex-
posure to antibiotic concentrations 4-times higher than the 
MIC for 100% of the dosing interval [40,41]. In an in vitro P. 
aeruginosa growth model, the PK/PD index predicting effi-
cacy for piperacillin-tazobactam was a maintained antibiotic 
concentration 5-times above the MIC [42]. In another similar 
study performed with a P. aeruginosa inocula of 108 CFU/mL, 
the consecution of a Cmin/MIC index  ≥3.8 avoided emergence 
of resistance [43]. 
Elimination half-lives for most β-lactams are 1-2 hours. 
After 30-minutes administration of standard doses at 8-hour 
intervals, serum concentrations decrease below 4-8 mg/L be-
fore the 4th-6th hours from administration, especially in septic 
patients with a volume of distribution (Vd) and renal clearance 
presumably elevated. For the treatment of severe or high bac-
terial load infections, produced by microorganisms exhibiting 
MIC ≥4 mg/L of the β-lactam, only elevated doses adminis-
tered by continuous or extended infusion reach free antibi-
otic concentrations exceeding 4-times the MIC [44-46]. Nev-
ertheless, serum antibiotic concentrations in the first hours 
(until the steady state is reached) are noticeably lower after 
continuous infusion than with a 30-min dose administration. 
Consequences of the delay may be important for critically 
ill patients or patients with severe immunodepression or se-
vere infection. In these circumstances it is necessary to start 
antibiotic treatment with an additional loading dose, by bo-
lus infusion, followed by the total daily dose administered as 
continuous infusion. The initial dose by bolus infusion allows 
early achievement of an elevated Cmax, favoring diffusion of 
the free fraction of the antibiotic to the infectious foci, on one 
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rial load, as VAP, an early and rapid ≥2 log10 CFU/mL decrease 
produced by the antibiotic treatment might decrease bacterial 
density below the cut-off level of granulocyte activity satu-
ration, allowing an optimal contribution for microorganism 
eradication. 
Another important consequence of the presence of a high 
bacterial load is the increased risk of selection of resistant mu-
tants. 
3) Mutation ability and development of resistance 
in P. aeruginosa. Frequency of emergence of resistant mu-
tants within P. aeruginosa populations ranges from 10-6 to 10-8 
depending on the antibiotic [82]. In the presence of agents 
damaging DNA (fluoroquinolones) and in biofilm-embedded 
bacterial growth, the basal rate of emergence of resistant 
mutants can be around 100 times increased. These are strains 
with mutations in genes involved in repair mechanisms of DNA 
replication errors. These hypermutants strains are usually seen 
in the mucoid phenotype present in patients with cystic fibro-
sis and other situations as chronic bronchial infections [83-87]. 
A bacterial density ≥ 107-108 CFU at treatment initiation 
involves high risk of selection and amplification of the re-
sistant subpopulation under the selective antibiotic pressure. 
Measures to counter this risk include:  a) reduction of the bac-
terial load through the control of the infectious foci (drainage, 
debridement, de-obstruction or removal of catheter or infect-
ed foreign body), b) initiation of treatment with associations 
of antibiotics not sharing the main resistance mechanism [88], 
and c) use of doses and/or routes of administration able to 
generate an antibiotic concentration higher than MIC for po-
tential resistant mutants in the infectious foci. 
If the P. aeruginosa infecting strain is susceptible to the 
antibiotics used and the dose and the administration schedule 
are appropriate, after 48-72 hours of treatment, the residual 
bacterial load in the infectious foci would presumably be lower 
to the one needed to generate a significant number of resist-
ant mutants, i.e., lower than the inferior limit of the spontane-
ous mutation rate (10-6). From then, the risk of development of 
resistance in the infectious foci could be considered as negligi-
ble and, if there are no other reasons justifying the association 
(see below), treatment can be continued as monotherapy with 
the β-lactam chosen based on the antibiogram.
Antibiotics (aminoglycoside, ciprofloxacin or levofloxacin) 
associated with the β-lactam during the first 48-72 h, among 
other purposes to avoid selection of resistant mutants, should 
be administered at doses achieving concentrations over the cor-
responding MPCs. Although MPCs are unknown and could not 
be predicted from MIC values, generally for these antibiotics 
they are from 8 to 12 times higher than the MIC.  In any case, 
the activity of these antibiotics is concentration-dependent 
and, higher the concentration in the infection foci, higher the 
bactericidal effect and lower the number of resistant mutants 
surviving antibiotic exposure. In vitro studies carried out with 
P. aeruginosa strains have shown that exposure to high tobra-
mycin concentrations for 1-4 h [89] and to high ciprofloxacin 
were absence of an initial loading dose, lack of consideration 
of the favorable effect of renal function impairment on the 
intermittent dosification and the recruitment of an insufficient 
number of patients to obtain significant differences [70]. The 
conclusion of three meta-analyses [71-73] including most of 
the above referred studies, was favorable to the use of extend-
ed or continuous infusion with respect to the risk of death. On 
the contrary, a third meta-analysis [74] including, among oth-
ers, studies carried out in patients with COPD exacerbations, 
did not show differences in outcome in relation to ways of an-
tibiotic administration. 
A recent study [75] showed that in septic patients attend-
ed at the Emergency department, a first-to-second  antibiotic 
dose delay of near 4h (for 6-hour dosing intervals) was seen in 
>50% patients. The delay in the second dose administration 
was associated with a significant increase in mortality. Antibi-
otic continuous infusion can preclude the risk of an eventual 
prolongation of the dosing interval. 
The main determinant for clinical response to an aminogly-
coside treatment is the  Cmax/MIC value [76]. For the reasons 
exposed below, the greatest efficacy for a treatment is obtained 
when Cmax/MIC ≥10. For a MIC value for P. aeruginosa of 2-4 
mg/L of tobramycin and gentamicin, the recommended Cmax is 
30-40 mg/L and for amikacin MIC of 8 mg/L, Cmax should be 
between 60 and 80 mg/L [77]. As later commented, usually these 
values are not achieved with standard doses.
2) Importance of the bacterial load in the infectious 
foci. In P. aeruginosa infectious foci as pneumonia, purulent 
tracheobronchitis in the intubated patient, secondary peri-
tonitis, neutropenic colitis and skin and soft tissue infections 
(gangrenous ecthyma, cellulitis in a diabetic foot wound or 
wound infection in severely burned patients), the bacterial 
load at antibiotic treatment initiation is usually high (≥107-108 
CFU). This bacterial inocula is between 100 and 1000 higher 
than standard inocula used in in vitro susceptibility tests. The 
intrinsic activity of most antibiotics decreases when bacterial 
load is high. In the case of β-lactams, this effect could be due 
to a reduced growth rate and/or expression of different PBPs 
with reduced affinity to β-lactams in the stationary phase of 
growth or the increase of β-lactamase concentrations due to 
bacterial lysis. Piperacillin and piperacillin-tazobactam seems 
the most affected by the inoculum size followed by ceftazi-
dime, with meropenem in the third place [78]. For β-lactams, 
time over MIC is the most important factor for low bacterial 
inocula or very susceptible microorganisms. However, when 
the microorganism is less susceptible or the inoculum is high, 
the β-lactam activity shows certain dependence of the antibi-
otic concentration [40]. 
The ability of granulocytes to eradicate microorganisms is 
saturable [79]. In rat models of pneumonia by P. aeruginosa, 
when the bacterial load was close to or higher than 2.5 x 106 
CFU/g of tissue, the bacteriolytic ability of granulocytes was 
surpassed and bacterial growth occurred [80,81]. The authors 
of these studies suggested that in infections with high bacte-
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domized, the most severe patients tended to be treated with 
antibiotic associations [107] and analyses were not adjusted 
by possible confounding factors. In a significant number of pa-
tients, the origin of bacteremia was an urinary tract infection 
or venous catheter removal, thus, non-severe infections and 
low bacterial load. In addition, in the aminoglycoside arm ne-
phrotoxicity masking the benefits of the association could not 
be ruled out since renal failure is an important prognostic fac-
tor in critically ill patients. On the other hand, in other studies, 
a favorable effect of the association versus monotherapy has 
been reported in the treatment of bacteremia caused by P. 
aeruginosa [2,108], particularly in neutropenic patients [109-
111], in cystic fibrosis exacerbations [112] and in a meta-anal-
ysis of studies on bacteremia by Gram-negative bacilli [113]. 
However, these results are neither conclusive because in the 
monotherapy arm patients treated with aminoglycosides were 
often included  [110,113]. The efficacy of aminoglycosides is 
lower than that of β-lactams [92,111] except in urinary tract 
infections [114]. 
The results of all these so far published studies on P. 
aeruginosa infections comparing monotherapy of a β-lactam 
with combinations of β-lactams and aminoglycosides, are at 
least questionable since the aminoglycoside concentration 
in serum was never optimized in the first 24-48 hours. This 
could be a critical issue explaining the apparent lack of in vivo 
synergy and other possible favorable effects of the combina-
tion, particularly in the case of P. aeruginosa infection for two 
reasons: the first one in relation to the mechanism of synergy 
and the second one related to the adaptive resistance phe-
nomenon. At low or intermediate tobramycin concentrations 
(<4 mg/L) the main mechanism of bacterial lysis is the block 
of protein synthesis at the ribosome, while at more elevated 
concentrations (≥8 mg/L), the main lytic mechanism is the 
aminoglycoside interaction with divalent cations stabilizing 
lipopolysaccharide molecules of the outer membrane. Since 
aminoglycosides molecules are bigger than Ca2+ and Mg2+ ions, 
their substitution by the aminoglycoside causes the disruption 
of the external membrane, with the subsequent increase in 
permeability [115]. In Gram-negative bacilli, and specially in P. 
aeruginosa, the outer membrane constitutes the main barrier 
for penetration of many antibiotics. The achievement of a high 
aminoglycoside concentration in the infectious foci is, proba-
bly, an important target if synergistic activity is to be obtained. 
The result of P. aeruginosa exposure to aminoglycosides 
is an early and rapid concentration-dependant bacterial lysis 
followed by a refractory phase characterized by a low and con-
centration-independant bacterial destruction known as adap-
tive resistance [24]. This phenotype of partial and transitory 
resistance is due to the fact that the aminoglycoside, even at 
subinhibitory concentrations, induces the expression of genes 
codifying the MexXY efflux pump [116]. A similar phenomenon 
is observed in anaerobic or hyperosmolar media, at acidic pH 
and in the presence of elevated concentrations of divalent ions 
(Ca2+ or Mg2+) [117]. This effect is more pronounced against 
P. aeruginosa. Several of these conditions are present in urine 
and bronchial secretion. Adaptative resistance justifies, among 
concentrations along 1 and 10h [90] widely reduce bacterial 
population without selection/amplification of resistant mu-
tants. However, in both experiments the addition of a second 
antibiotic was needed to prevent regrowth of the residual bac-
terial population that remained susceptible. 
At the 2nd-3rd day of treatment, when deescalation to 
monotherapy is considered, most patients remain colonized by 
P. aeruginosa in mucosa and bronchial secretion (in case of 
pneumonia, tracheal intubation or previous bronchial patholo-
gy), especially if no inhaled antibiotic treatment with tobramy-
cin, colistin or aztreonam had been administered. Persistence 
of bronchial colonization does not justify by itself prolonga-
tion of iv administration of the aminoglycoside more than 3-5 
days. Despite reaching a Cmax in serum ≥10 times the MIC, 
there is a low probability that the concentration and the ac-
tivity of the aminoglycoside in bronchial secretion exceeds 
the MPC, thus hardly precluding development of resistance 
at the expense of a higher risk of renal toxicity secondary to 
treatment prolongation. The same concept could be applied to 
colistin administered by systemic route, but not to ciprofloxa-
cin and levofloxacin with better diffusion to bronchial secre-
tion.
4) Importance of an appropriate empirical treatment. 
Studies performed in patients with VAP [13,91] or bacteremia 
[2-4,8,11,92-94] caused by P. aeruginosa showed high mor-
tality rates if the initial empirical antibiotic treatment is not 
appropriate. Non appropriate antibiotics are those for which 
the microorganism shows resistance in in vitro susceptibility 
tests. Early administration of an appropriate antibiotic treat-
ment has special relevance when the infection presents clini-
cal or biological severity criteria, the patient suffers important 
immunodepression or comorbidities or has advanced age. 
These are particularly frequent clinical situations in patients 
with P. aeruginosa infections [3,95-97]. Given the current high 
prevalence of P. aeruginosa strains resistant to β-lactams, 
treatment initiation with a β-lactam associated with amika-
cin, ciprofloxacin or colistin (chosen based on local resistance 
rates) increases the probability of the appropriateness of the 
initial empirical schedule, that is, the P. aeruginosa strain is 
at least susceptible to one of the two antibiotics administered 
[91,93,94,98,99].
5) Value of antibiotic associations. Usually, the asso-
ciation of a β-lactam and an aminoglycoside shows in vitro 
synergistic activity. However, in clinical practice, the potential 
synergy of the association does not seem to turn into a tangi-
ble improvement of prognosis estimated as survival rate. Most 
studies carried out in patients with bacteremia [5,92,94,100-
104] or VAP [91,105,106] by P. aeruginosa, as well as several 
meta-analyses [98,99,107], did not found significant differ-
ences in mortality rates between patients receiving β-lactam 
monotherapy and those receiving a β-lactam and aminogly-
coside association. Nevertheless, there are several aspects raising 
doubts with respect to the strength of these results. Most 
studies were retrospective analyses, treatments were not ran-
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olar space and specially to the bronchial secretion [136-141] 
and the potential loss of activity in both sites. A reduction in 
the activity of tobramycin has been observed in the presence 
of pulmonary surfactant, particularly at low concentrations 
(0.25-1 x MIC) [142], probably due to its linkage to surfactant 
phospholipid proteins. In bronchial secretion, aminoglycosides 
are partially inactivated, mainly if the sputum is purulent, due 
to the electrostatic binding to mucin polysaccharides and to 
the DNA, to the presence of divalent cations and to pH ≤ 7 
[143]. Concentrations up to 25 times higher the MIC of tobra-
mycin are required to achieve bactericidal activity in sputum 
[144,145].
Even though clinical experience does not permit to firmly 
rule out the existence of a favorable result when associating a 
β-lactam and an aminoglycoside, if a benefit exists, it does not 
imply a significant improvement in the prognosis and it does 
not justify the risk of the aminoglycoside nephrotoxicity. In 
most clinical situations, the treatment of choice for a β-lactam 
susceptible P. aeruginosa infection is β-lactam monotherapy 
except in the following cases: 1) during the first 72 hours if 
the infection presents criteria of severe sepsis or septic shock, 
2) in the neutropenic patient, and 3) in nervous central system 
(meningitis, abscess) or endovascular (endocarditis) infections. 
Use of associations including a β-lactam should be considered 
even for the treatment of infections caused by β-lactam re-
sistant pathogens, especially if the resistance level is moderate 
(MIC 2-4 times higher than the breakpoint value). In this sit-
uation, the potential synergy with the second antibiotic could 
revert β-lactam non-susceptibility, if succeed in lowering the 
MIC below the resistance level. 
6) Clinical efficacy of different antibiotics as mono-
therapy. Clinical experience evidences that monotherapy with 
β-lactams shows higher efficacy and/or lower toxicity than 
monotherapy with aminoglycosides [92,111,114] or colistin 
[146-148] and similar to monotherapy with a fluoroquinolone 
(ciprofloxacin) [149-151] in the treatment of gramnegative in-
fections, including those by P. aeruginosa. However, in some 
infection sites, as in external malignant otitis, prostatitis, or 
cystic fibrosis bronchial infections, the use of ciprofloxacin 
may have advantages over a β-lactam, based on the possibility 
of oral administration, better penetration in the infectious foci 
and the probable greater activity in biofilms.
7) Measures to increase antibiotic concentrations 
in the infectious foci. As mentioned in points 1 and 2, to 
optimize the PK/PD index and to avoid selection/amplifi-
cation of resistant subpopulations, high (aminoglycosides, 
fluoroquinolones) and maintained (β-lactams) antibiotic con-
centrations are required in the infectious foci. Nevertheless, 
in certain infection sites (as in pneumonia in the intubated 
patient, ventriculitis, meningitis), even with the maximum 
tolerated dose, MPCs are not exceeded or the associated tox-
icity is unacceptably high. In these cases, the possibility of di-
rectly introducing the antibiotic into the infectious foci using 
others, the administration of aminoglycosides as single daily 
doses. If after the first aminoglycoside dose, a Cmax approxi-
mately 10 times the MIC is not reached, the intrinsic bacteri-
cidal activity of the antibiotic is lower than optimal, not sur-
passing the MPC and reduces the possibility and/or the degree 
of β-lactam synergy. This decrease in efficacy precisely occurs 
during the first 24-48 hours of treatment, when there is a 
need for a rapid elimination of the high bacterial load and for 
countering selection of resistant mutants, this justifying the 
β-lactam and aminoglycoside association. Clinical experience 
supports the importance of optimizing the aminoglycoside PK/
PD parameters from the beginning. A published study [118] 
analyzed outcome in 78 patients with pneumonia treated with 
antibiotic regimens including aminoglycosides with the aim 
of determining if optimization of PK/PD parameters result in 
more rapid therapeutic responses (defined as days until fever 
and leukocytosis resolution). The logistic regression analysis 
predicted 90% probability of fever and leukocytosis resolution 
after 7 days if during the first 48h treatment with the amino-
glycoside a Cmax/MIC >10 ratio was reached [118]. In another 
study including 38 patients with bacteremia by P. aeruginosa, 
the probability of clinical cure was ≥90% when the Cmax/MIC 
ratio was at least 8 [119]. 
Until mid 90’s, aminoglycosides (gentamicin, netilmicin and 
tobramycin) were used at doses of 3 to 5 mg/kg/day with bid or 
tid schedules. These regimens reached a Cmax of approximately 
5 mg/L from day 2-3 on [106,120,121]. The potential effects on 
outcome when aminoglycosides are administered at suboptimal 
doses are hardly valorable in infections by P. aeruginosa (to-
bramycin MIC are usually 2 mg/L). From 1990’s on, schedules 
progressively changed to single daily doses of 5-7 mg/kg/day 
(gentamicin and tobramycin) and of 15-20 mg/kg/day for ami-
kacin [122]. Nevertheless, even with these doses, often Cmax 
continues to be suboptimal (especially for the treatment of P. 
aeruginosa infections) due to the elevated Vd and/or increase 
of renal clearance normally present in patients with severe 
sepsis or septic shock, mechanical ventilation, neutropenia, 
polytraumatism, severely burn, cystic fibrosis or morbid obesity 
(if doses are calculated for the lean body mass) [123-126]. In 
an ICU study, septic patients were treated with a mean gen-
tamicin dose of 6.6 ± 2.3 mg/kg and only 1 out of 24 patients 
(4%) reached the desired Cmax ≥30 mg/L [127]. In another 
study carried out in patients with severe sepsis or septic shock 
treated with an amikacin initial dose of 25 mg/kg, the desired 
Cmax of at least 60 mg/L was not reached in up to 30% of cas-
es [128]. Other authors have reported similar results [129-133]. 
In a 2013-14 French study, two years after the implementation 
of a guideline for aminoglycoside administration [77], 37% 
prescriptions were not in line with the recommendations [134]. 
With the aminoglycoside once daily administration the risk of 
renal toxicity is reduced through the reduction in the time that 
the proximal tubule is exposed to the antibiotic. Treatment du-
ration for the aminoglycoside in the combined therapy with a 
β-lactam should be limited to the first 3-5 days [135].
In VAP patients, a low aminoglycoside Cmax might be 
primarily unfavorable due to its limited diffusion to the alve-
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criteria, the radiologic image is extensive 
or shows cavitations, or the isolated strain 
is multidrug resistant, inhaled treatment 
administration of tobramycin, colistin or 
aztreonam through a vibrating-membrane 
nebulizer should be considered. Presence 
of severe hypoxia (PaO2/FiO2 < 200) might 
contraindicate the use of inhalatory route.
Table 3 shows main recommendations 
in relation to antibiotic treatment for acute 
invasive infections by P. aeruginosa.
ANTIBIOTICS ACTIVE AGAINST  
P. aeruginosa
β-lactams. Nowadays, in most Spanish 
hospitals resistance rates in P. aeruginosa 
to piperacillin-tazobactam, ceftazidime, 
cefepime, aztreonam, imipenem or mero-
penem are ≥20% (table 2).  Ceftolozane-ta-
zobactam is active against nearly 95% 
isolates and the ceftazidime-avibactam 
association restores ceftazidime susceptibility in nearly 80% 
resistant strains. With the exception of imipenem, poorly sta-
ble at room temperature, all other β-lactams active against P. 
aeruginosa should be administered at high doses and using 
extended or continuous infusion after an initial loading dose. 
This recommendation is based on: their time-dependant bac-
tericidal activity, the possible inoculum effect of a high bac-
terial load (present at treatment initiation), the need for opti-
mization of the PK/PD parameter for the high MIC against P. 
aeruginosa, the increase in Vd and/or renal clearance [170] and 
the need to exceed the MPC. In relation to the latter, table 1 
shows MPC values for different β-lactams against a P. aerugi-
nosa strains not harboring additional resistance determinants. 
Several studies have reported for ceftazidime and meropenem 
values similar to those shown in table 1 [171-173]. With a MPC 
value >32 mg/L of ceftazidime, cefepime, aztreonam, pipera-
cillin-tazobactam and imipenem, the probability that concen-
trations of these antibiotics in serum are within the mutant 
selection window is very high, even when administered at 
maximum doses by extended/continuous infusion. The risk is 
especially high if the infection involves a bacterial load equal 
to or higher than the spontaneous mutation rate (10-6-10-8 
CFU). The risk is moderate for meropenem (MPC of 8 mg/L) ad-
ministered at 6 g daily dose by extended infusion, and very low 
for ceftolozane-tazobactam (MPC of 2 mg/L) at 1.5-3 g dose 
by 3-4 hours infusion every 8 hours. In an in vitro study us-
ing one wild-type and one hypermutant P. aeruginosa strains 
exposed to ceftazidime, meropenem and ceftolozane-tazo-
bactam, high-level resistance first to ceftazidime and after to 
meropenem was rapidly developed in both strains [31]. None 
of the selected mutants showed cross-resistance with ceftolo-
zane-tazobactam. Development of resistance to ceftolo-
zane-tazobactam was slower and only was of high-level in 
the hypermutant strain [31]. Other studies have confirmed the 
the inhalatory, intrathecal or other routes (depending on the 
infection site) should be considered. Antibiotic administration 
by the inhalatory route allows concentrations in bronchial mu-
cous and the epithelial lining fluid around 100 times higher 
than those obtained with the same dose by iv route. This result 
in a higher probability of bacteriological eradication, even for 
microorganisms considered as resistant in in vitro susceptibil-
ity tests together with a reduction in the risk of selection and 
growth of the resistant population.  
The review of clinical experience on the treatment of P. 
aeruginosa respiratory infections using inhaled antibiotics sur-
passes the extension limit of the present document. In chronic 
respiratory infections by P. aeruginosa in cystic fibrosis pa-
tients, inhaled tobramycin, colistin or aztreonam are consid-
ered treatments of choice, from the first exacerbation by P. 
aeruginosa, even in case of strains susceptible to β-lactams 
[19,152]. Studies performed in VAP patients [153-164], and 
several meta-analyses on VAP [165-167] or bronchiectasis 
infections [168], indicate that the addition of inhaled antibi-
otics improves clinical success and bacteriological eradication, 
especially when causal microorganisms harbour resistance 
mechanisms. In a study on patients with VAP by P. aerugino-
sa, the administration of inhaled antibiotics was compared 
with the administration of the same compounds by iv route, 
randomly assigning patients to receive ceftazidime and ami-
kacin as treatments [169]. In the inhaled treatment arm, 
several patients were infected by strains exhibiting interme-
diate resistance to the antibiotics used, while in the iv treat-
ment arm, in case of intermediate resistance to amikacin, this 
drug was changed to ciprofloxacin. No statistically significant 
differences in clinical outcome were observed. Resistances on-
ly emerged in the iv treatment arm [169]. In the respiratory 
infection by P. aeruginosa, if the infection presents severity 
Table 3  Recommendations for antibiotic treatment of acute 
invasive infection produced by P. aeruginosa
1. Consider surgical control of the foci (drainage, debridement) and removal of any infected foreign body 
(catheter u others).
2. Include a β-lactam with activity against P. aeruginosa.
3. Choose the β-lactam having: a) the highest probability to achieve the optimal value of the adequate 
pharmacokinetic/pharmacodynamic index, and b) the lowest risk of selection/amplification of the 
resistant subpopulation. 
4. For empirical treatment schedules, consider possible antibiotics associations during the first 48-72 h, 
in order to: rapidly decrease the bacterial population, avoid selection of resistant mutants (or resistant 
subpopulations in heteroresistant strains) and to increase the probability of the strain to be susceptible 
at least to one of the two antibiotics. 
5. For directed treatment schedules, consider possible antibiotics associations if the infection presents 
criteria for severe sepsis or septic shock, in central nervous system infections, in endocarditis, in case of 
neutropenia (< 500/cells/mm3) and when P. aeruginosa is resistant to β-lactams.
6. Whatever antibiotic is chosen, it is essential to optimize the dose, route and way of administration. 
Consider the use of the inhalatory route in case of a severe respiratory tract infection or caused by a 
multidrug resistant strain.
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including aztreonam) showed in vivo synergism, which was 
bad correlated with in vitro interaction results [186]. Another 
possible synergistic mechanism for β-lactam combinations is 
the complementarity of PBPs inhibition profiles. In a recently 
published study [187], the association of cefepime, piperacillin 
or meropenem with zidebactam, a non- β-lactam PBP2 specific 
inhibitor, was synergistic against MDR and MBL-producing P. 
aeruginosa strains. However, there are not clinical experience, 
not even in infection animal models, supporting the potential 
advantage of the combination of a potent PBP2 inhibitor 
(carbapenem) with a potent PBP3 inhibitor (ceftazidime, 
cefepime or aztreonam). 
Aminoglycosides. Tobramycin is the aminoglycoside 
showing the highest intrinsic activity against P. aeruginosa, 
being two-times more active than gentamicin and from 3 to 
4 times than amikacin. Nevertheless, amikacin is susceptible to 
inactivation by a lower number of enzymes, thus being active 
against a higher percentage of P. aeruginosa isolates (90-95%) 
compared to tobramycin (80%). 
The concentration-dependent bactericidal activity of 
aminoglycosides reaches its optimal efficacy in the treat-
ment of P. aeruginosa infection when a Cmax/CMI ≥10 ratio 
is obtained in the first 24-48 hours of treatment initiation 
[118,119]. Aminoglycosides, due its hydrophilic nature, are 
distributed in the interstitial space and renally eliminated. The 
increase in Vd and in renal clearance, observed in critically ill 
patients with an important systemic inflammatory response, 
significantly reduces the aminoglycoside concentration in se-
rum after the first dose. The recommended dose in the first 48-
72 h of treatment, in patients with normal renal function and 
severe P. aeruginosa infection, is up to 8 mg/kg for gentamicin 
or tobramycin and of 20-30 mg/kg for amikacin [77].
The combination of an aminoglycoside and a β-lactam 
might be in vitro synergistic against gramnegative bacilli by 
means of the increase in the permeability of the external 
membrane, as previously commented. Another mechanism 
that could contribute, at least in part, to the synergy is the 
one observed in AmpC-producing P. aeruginosa resistant to 
cefepime. The addition of tobramycin at 7 mg/kg/day doses 
suppress protein synthesis, and with that, β-lactamase expres-
sion, facilitating the cephalosporin activity [188].
Fluoroquinolones. The current resistance rate to cipro-
floxacin and levofloxacin in P. aeruginosa, in most Spanish 
hospitals, exceeds 30% (table 2). Ciprofloxacin is intrinsically 
more active than levofloxacin (MIC 2-4 dilutions lower). 
The concentration-dependent bactericidal activity of 
fluoroquinolones reaches an optimal efficacy with Cmax/MIC 
>8. Nevertheless, the bactericidal effect of fluoroquinolones 
is slower than that of aminoglycosides and lysis of resistant 
mutants requires longer exposures. Bacteriological eradication 
without resistance development has been related with AUC24h/
MIC >100 [189,190]. The combination of both indexes mini-
mizes resistance emergence [90]. MPC of ciprofloxacin and 
levofloxacin is 2 and 8 mg/L, respectively [191]. Diffusion of 
fluoroquinolones (especially levofloxacin) to cerebrospinal flu-
greater ability of ceftazidime versus meropenem in selecting P. 
aeruginosa resistant mutants both from wild-type and hyper-
mutant strains [174]. 
In clinical practice, most isolates of P. aeruginosa harbors 
one or more resistance mechanisms and MPC values are higher 
than those for fully susceptible strains. In these cases, failure 
and/or resistance development may occur with meropenem 
and, eventually, with ceftolozane-tazobactam monotherapies, 
even at high doses.
The main side effect with the use of a β-lactam high dose 
is neurotoxicity produced by inhibition of GABA- GABAA recep-
tors binding, characterized by a slow and progressive appear-
ance of somnolence, confusion, disorientation, agitation, my-
oclonus, asterixis, seizures, non-convulsive epileptic status and 
coma. The electroencephalogram shows a diffuse slow wave 
activity with triphasic waves, suggestive of toxic encephalopa-
thy. Neurotoxicity is more frequent with cefepime, followed by 
ceftazidime, cefazoline and the remaining β-lactams. Patients 
with pathologies involving the central nervous system, with 
renal impairment and advanced age are especially vulnerable 
[175,176]. Some authors consider that steady state concentra-
tions should not exceed the 100 mg/L threshold to avoid neu-
rological toxicity with piperacillin, aztreonam or ceftazidime 
[177,178]. 
Piperacillin-tazobactam has been identified as a factor 
responsible for the delay in renal function restoration in the 
critically ill patient [179].
The review of the resistance mechanisms to different 
β-lactams in table 1 shows that ceftazidime and piperacillin 
share the same primary resistance mechanism, as well as oc-
curs for cefepime and aztreonam and for meropenem and im-
ipenem. Resistance to any of these antibiotics makes probable 
(but not certain) the resistance to its couple [180].
High number of in vitro studies on the association of 
two β-lactams or one β-lactam with other antibiotics, mainly 
aminoglycosides and fluoroquinolones, has been published. 
Chromosomal cephalosporinases (AmpC) of the species 
Enterobacter, Citrobacter, Serratia and Pseudomonas hydrolyze 
aztreonam, but the half-life of this reaction is long enough to 
maintain the enzyme inactivated along several generations of 
bacterial growth. In this way aztreonam can protect ceftazidime, 
and specially cefepime, from hydrolysis by AmpC in P. aeruginosa 
strains resistant by derepressed production of the enzyme [181-
185]. The benefit is higher in the case of cefepime due to its 
more rapid cross of the external bacterial membrane. However, 
clinical experience is limited to a study including 13 patients 
with infection by P. aeruginosa resistant to all β-lactams treated 
with the association of cefepime plus aztreonam. Outcome 
was favorable for 69% of cases. Nevertheless, 11 out of 13 
patients additionally received an aminoglycoside and 5 inhaled 
colistin.  Aztreonam is resistant to hydrolysis by MBLs. It could 
be associated with ceftazidime-avibactam for the treatment 
of infections caused by P. aeruginosa strains producing a MBL 
plus derepressed AmpC. In a Galleria mellonella larvae model 
of P. aeruginosa infection, several β-lactam associations (not 
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after standard doses does not exceed 2-3 mg/L. Although 
its bactericidal activity is concentration-dependent, the 
therapeutic margin is very narrow and the increase in 
serum concentrations is not possible due to the risk of renal 
toxicity. The activity decreases in the presence of high inocula 
[202,203]. In P. aeruginosa rat models of pneumonia, a 
fAUC0–24 /MIC of 40 predicted a bacterial reduction ≥ 2 log10 
[204]. Some P. aeruginosa strains, apparently susceptible to 
colistin, presented heteroresistance [205] with the MIC of the 
resistant subpopulation far above the achievable maximum 
concentration in serum. Colistin should not be used as 
monotherapy, especially if the MIC is > 1 mg/L, the bacterial 
load is high or in the case of low accessible foci (lung, CNS). 
The association with a β-lactam (cefazidime or meropenem), 
a fluoroquinolone (ciprofloxacin or levofloxacin) or rifampicin 
can exert synergistic effects [206-211]. It is recommended to 
start treatment with a 6-9 MU iv loading dose to avoid the 
delay of 48-72 hours needed to reach the stationary state 
[212,213], followed by iv 4.5 MU/12 hours. Nevertheless, in a 
recent study [214] no relation between 28-days mortality and 
administration of a loading dose followed by high doses (9 
MU/days) was observed when compared with the use of lower 
doses (4-6 MU/day) without loading dose. On the contrary, 
renal toxicity and appearance of seizures were significantly 
more frequent with the use of high doses. The most frequently 
isolated microorganisms were Acinetobacter baumannii and 
Klebsiella pneumoniae, and against both, colistin MIC was 
low (MIC90 0.5 mg/L). Thus, probably, an optimal exposure was 
achieved with both doses [215]. Until more experience in the 
treatment of infections caused by microorganisms exhibiting 
MIC ≥ 2 mg/L is available, the administration of a loading dose 
followed by high doses should be considered.  
Diffusion of colistin in the alveolar space and the bronchial 
secretion is limited [216], and its activity significantly decreases 
in the presence of mucus [217]. As well, concentration in cere-
brospinal fluid is only 5% of the serum concentration [218]. 
Fosfomycin. Against nearly 33% P. aeruginosa 
strains, MIC of fosfomycin is ≤64 mg/L. Its time-dependent 
bacteriostatic activity is highly influenced by the inoculum size 
[219]. Heteroresistance is frequent among susceptible strains, 
and for this reason monotherapy is not recommended. The 
association with tobramycin [220,221], amikacin [222,223], 
ciprofloxacin [224,225] and different β-lactams [226-229] is 
frequently synergistic and decreases emergence of resistance 
[220-222]. Clinical experience is limited to the treatment 
of MDR P. aeruginosa exacerbations of cystic fibrosis. In the 
largest published study, 30 exacerbations in 15 patients treated 
with iv  5 g/8h fosfomycin associated with tobramycin, colistin 
or a β-lactam were analyzed [230]. The authors considered 
that treatment outcome was favorable. In a literature review 
analyzing 6 studies, including 33 patients treated with 
fosfomycin (associated with other antibiotic in 25 cases), 
91% patients had a favorable outcome [231]. Optimal efficacy 
against P. aeruginosa is obtained with 16-24 g/day continuous 
infusion [226]. The disodium salt for iv administration contains 
13.5 mEq of sodium per gram; caution is needed when 
id, lung parenchyma, bronchial secretion and prostate is supe-
rior to that of β-lactams, aminoglycosides and colistin. 
In in vitro studies carried out with P. aeruginosa, the 
association of levofloxacin and imipenem precluded emer-
gence of resistance, even when strains exhibiting intermediate 
resistance to one or both antibiotics due to loss of OprD or 
efflux pumps overexpression were used [192,193]. In several 
studies, the association of levofloxacin with meropenem had 
more rapid bactericidal effect and resulted in resistance sup-
pression [194] or meropenem MPC decrease [195], even when 
the strain was resistant to levofloxacin [196]. Levofloxacin and 
meropenem are eliminated by MexAB and the overexpression 
of this pump should affect both. The authors suggest that the 
β-lactam access to the pump through the periplasmic space 
could saturate its ability to extract levofloxacin from the cyto-
plasm [194]. The association of ceftazidime or cefepime with a 
fluoroquinolone (ciprofloxacin, levofloxacin or moxifloxacin) at 
0.5 x MIC concentrations was synergistic for more than 50% P. 
aeruginosa strains [197].  However, in another study, the asso-
ciation of ceftazidime with ciprofloxacin led to emergence of 
resistance due to overexpression of MexAB [198].
Clinical experience indicates that ciprofloxacin is similar 
to [151] or better than imipenem [149] in the treatment of 
severe nosocomial pneumonia. Ciprofloxacin associated to 
metronidazole was similar to imipenem in intraabdominal 
infections [199] and equivalent to the association of 
ceftazidime and amikacin in febrile episodes in neutropenic 
patients [150]. In a study including 740 patients with VAP, 
treatment with meropenem monotherapy (1 g every 8 hours) 
was compared with meropenem associated with ciprofloxacin 
(400 mg/12 hours), in both cases by iv route. Treatment 
allocation was randomized. No differences in mortality, days 
in the ICU or hospital, clinical or microbiological response or 
emergence of resistance were observed. Nevertheless, in the 
analysis of the subgroup of 56 patients who had infection due 
to P. aeruginosa, Acinetobacter spp., and multidrug-resistant 
Gram-negative bacilli, the combined initial treatment was 
appropriate in 84% patients (versus 18.8%; p< 0.001) and the 
response was favorable for the association in microbiological 
eradication (64% versus 29.4%; p = 0.05) and favorable but 
non-significant in 28-days clinical resolution rates, days in the 
ICU and days with mechanical ventilation [200]. In the analysis 
of a series of 235 episodes of bacteremia by P. aeruginosa, 
definitive treatments with associations including ciprofloxacin 
showed a significantly lower 30-days mortality if the strain was 
susceptible. On the contrary, the association with tobramycin 
did not modify the prognosis [2]. A similar result was reported 
in another study on patients with bacteremia by gramnegative 
bacilli and Pittsburgh score <4 [201].
The use of high fluoroquinolone doses, exceptionally 
might produce confusion, orofacial dyskinesias, myoclonus, 
psychosis and non-convulsive epileptic status [175] by GABAA 
inhibition or NMDA receptor activation. 
Colistin. Around 98% P. aeruginosa strains are colistin 
susceptible with MICs of 0.5-1 mg/L (table 2). Colistin Cmax 
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within the previous 30-90 days, and in hospitalized patients 
admitted to units with a prevalence of MDR/XDR P. aerugino-
sa ≥10-20% for >3-5 days or which have history of previous 
colonization/infection by MDR/XDR P. aeruginosa. Among risk 
factors for selection of MDR/XDR strains we do not include ex-
posure to β-lactams not active against P. aeruginosa, fluoro-
quinolones or aminoglycosides, since, under these conditions, 
the probability of colonization by strains resistant to antipseu-
domonal β-lactams is lower.
If the patient fulfills any of the above criteria, treatment 
with a β-lactam different from the one received within the 
previous 90 days should be used. By order, preference should 
be given to 1.5-3 g/8 h iv ceftolozane-tazobactam, 2 g/8 h iv 
meropenem and 2 g/8 h iv ceftazidima or 4.5 g/6 h iv piper-
acillin-tazobactam. They should be administered as extended 
infusion (ceftolozane-tazobactam, meropenem) or continuous 
infusion with a loading dose (ceftazidime, piperacillin-tazobac-
tam), together with a second antibiotic as 25 mg/kg/día iv ami-
administered to patients with heart insufficiency or under 
hemodialysis. Rapid high doses administration may produce 
hypopotassemia. 
ANTIBIOTICS OF CHOICE FOR THE TREATMENT OF 
INFECTIONS CAUSED BY P. aeruginosa
Empirical treatment (figure 1). Empirical selection of the 
most appropriate antibiotic treatment for a possible infection 
by P. aeruginosa is based on: a) presence of severity criteria 
and b) presence of risk factors for infection by a strains har-
boring resistance mechanisms. Severity criteria include criteria 
of severe sepsis or septic shock, severe immunodepression (es-
pecially neutropenia <500 cells/mm3), and infections involving 
high bacterial load, being not surgically controllable, as exten-
sive pneumonia or pneumonia with cavitations/necrosis. The 
possibility of infection by a MDR strain should be considered in 
patients treated with a β-lactam active against P. aeruginosa 
Figure 1  Election of empirical antibiotic treatment active against P. aeruginosa
— Criteria for severe sepsis or septic shock?
— Foci with high bacterial load? (a) 
— Severe immunodepression (neutropenia < 500 cells/mm3)? (b) 
— Risk for colonization by P. aeruginosa MDR? (c)
YES (to any) NO (to all)
β-lactam (d) active against P. aeruginosa different 
from the one used in the previous 90 days. In order of 
preference: ceftolozane-tazobactam >  
ceftazidime-avibactam > meropenem >  
ceftazidime o piperacillin-tazobactam
+
amikacin or colistin (e)
+
Control of the infectious FOCI
(drainage, de-obstruction, debridement and/or removal 
of possible infected foreing body).
a) High bacterial load not surgically correctable (extensive pneumonia or pneumonia with necrosis/cavitation)
b) Includes neutropenia < 500 cells/mm3 and treatment with corticoid doses >20 mg/kg during >3 weeks
c)Treatment within the last 30-90 days with a β-lactam active against P. aeruginosa, admission during > 3-5 days in an hospitalization unit with a prevalence of MDR P. 
aeruginosa >10-20% or previous history of colonization/infection by MDR P. aeruginosa
d) Initial loading dose followed by high doses administered as continuous (or extended) infusion during the first 48-72 h
e) According to local epidemiology and susceptibility of possible previous isolates 
f) Monotherapy in case of urinary tract infection or venous catheter infection. Association with amikacin or fluoroquinolone (levofloxacin or ciprofloxacin) in situations 
with high bacterial load (pneumonia) 
g) Ciprofloxacin as treatment of choice for malignant external otitis, prostatitis and bronchial infection in patients with cystic fibrosis
β-lactam (d) active against P. aeruginosa: meropenem, 
piperacillin-tazobactam or ceftazidime 
 
+ (f)
amikacin or ciprofloxacin (g)
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rial load. In case of resistance to meropenem, treatment can be 
ceftolozane-tazobactam, ceftazidime or piperacillin-tazobac-
tam. Again, the decision should be taken based on the bacterial 
inoculum size. 
c) Strain susceptible to all β-lactams.
In this case, treatment options can be meropenem, cef-
tazidime or piperacillin-tazobactam. However, in VAP, severe 
pneumonia in COPD patients or in patients with bronchiecta-
sis, and pneumonia with cavitation/necrosis, treatment with 
ceftolozane-tazobactam at 3 g/8 hours should be considered 
due to the high risk of resistance emergence. 
In any of the three previous situations, in case of septic 
shock and in neutropenic patients, along the first 48-72 hours 
of directed treatment, an additional antibiotic (chosen ac-
cording to the strain susceptibility) can be added: 400 mg/8 h 
ciprofloxacin or 8 mg/kg/day iv tobramycin (25-30 mg/kg/day 
amikacin in case of resistance to tobramycin). Occasionally, the 
resistance pattern makes necessary associations with colistin 
4.5 MU/12 h or fosfomycin at 16-24 g/day iv dose administered 
as continuous infusion. Inhaled antibiotics (tobramycin, colistin 
or aztreonam) are reserved for cases of severe pneumonia or 
pneumonia caused by MDR P. aeruginosa strains. Nevertheless, 
their use should also be considered for infections caused by 
strains not harboring resistance mechanisms when the patient 
is intubated or suffers a relevant chronic bronchial patholo-
gy (GOLD-4 COPD, cystic fibrosis, bronchiectasis, bronchiolitis), 
circumstances in which the high bacterial load together with 
the limited antibiotic diffusion to bronchial secretions drives to 
an important risk for treatment failure and/or resistance emer-
gence.
The treatment of CNS infections by P. aeruginosa poses 
two additional problems: antibiotic diffusion through the 
kacin as single daily dose or colistin (loading dose of 6-9 MU 
iv followed by 4.5 MU/12 h iv). For the election of the second 
antibiotic, it should be taken into account the epidemiology of 
the unit or hospital, and in the case of previous colonization/
infection by P. aeruginosa, the susceptibility of the isolate.
If the patient does not fulfill severity criteria and has not 
risk factors for infection by a MDR/XDR P. aeruginosa strain, 
treatment could be initiated with a β-lactam (meropenem, cef-
tazidime or piperacillin-tazobactam) alone (urinary tract infec-
tion or venous catheter infection) or associated with amikacin 
or a fluoroquinolone (levofloxacin or ciprofloxacin) when bac-
terial load is higher (pneumonia).
In any of the previous situations, adequate surgical control 
of the infectious foci (drainage, de-obstruction, debridement) 
and/or removal of the infected foreign body (catheter or 
others) is critical.
Once culture results and antibiogram are available, treat-
ment should be adjusted to the susceptibility of the isolated 
microorganism. If P. aeruginosa infection is confirmed and clin-
ical evolution is favorable, from the 3rd day on treatment can 
be continued as monotherapy with a β-lactam chosen in ac-
cordance with the antibiogram. If all cultures are negative and 
clinical evolution is favorable, from the 3rd day on treatment 
can be continued as monotherapy with the initial β-lactam. If 
a rectal swab is available, and the patient is not colonized by P. 
aeruginosa, treatment continuation with a β-lactam not active 
against this microorganism can be considered.
Directed treatment. Election of antibiotic treatment when the 
susceptibility profile of the isolated P. aeruginosa strain is known, 
can be made according to the following recommendations: 
a) Strain resistant to meropenem, ceftazidime and pipera-
cillin-tazobactam, but susceptible to ceftolozane-tazobactam 
and ceftazidime-avibactam. 
Against these strains, MIC of ceftolozane is often 2-4 
mg/L. A possible treatment is 3 g/8 h iv ceftolozane-tazobac-
tam. ESBL- or class A carbapenemase (GES o KPC)- producing P. 
aeruginosa strains can be resistant to ceftolozane-tazobactam, 
maintaining susceptibility to ceftazidime-avibactam that can 
be used at 2.5 g/8 h iv doses. If the strain produces a MBL-type 
carbapenemase, therapeutic options are limited to the use of 
associations of aztreonam with ceftazidime-avibactam with or 
without colistin.
b) Strain resistant to one of the β-lactams active against 
P. aeruginosa. 
In case of resistance to ceftazidime and/or piperacillin-ta-
zobactam, treatment can be ceftolozane-tazobactam, ceftazi-
dime-avibactam or meropenem. The election depends on the 
risk of emergence of resistance, which in turn is related with 
the expected size of the bacterial load in the infectious foci. 
If the infection involves a high bacterial load (pneumonia), it 
is adviced to give priority to the antibiotic having the greatest 
probability to surpass the MPC, in this case, ceftolozane-tazo-
bactam. Meropenem can be used for urinary tract infections, 
venous catheter infections or other infections with low bacte-
Antibiotic Posology
Ceftazidime 1-2 g loading dose + 6 g/24 h CI
Ceftazidime-avibactam 2/0.5 g/8 h EI
Piperacillin-tazobactam 2/0.25 g loading dose + 16/2 g/24 h CI
Ceftolozane-tazobactam 1/0.5 or 2/1 g/8 h EI
Aztreonam 1-2 g loading dose + 6 g/24 h CI
Meropenem 1-2 g loading dose + 2 g/8 h EI
Fosfomycin 2-4 g loading dose + 16-24 g/24 h CI
Colistin 6-9 MU loading dose + 4.5 MU/12 h
Ciprofloxacin 400 mg/8 h in 30-60 minutes
Levofloxacin 500 mg/12 h in 30-60 minutes
Tobramycin 8 mg/kg/24 h in 60 minutes 
Amikacin 25 mg/kg/24 h in 60 minutes
Table 4  Initial posology of antibiotics with 
activity against P. aeruginosa for the 
treatment of severe infections
CI: continuous infusion; EI: extended infusion (3-4 h); MU: million units
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10. Thaden JT, Park LP, Maskarinec SA, Ruffin F, Fowler VG, Jr., van DD. 
Increased mortality associated with bloodstream infections caused 
by Pseudomonas aeruginosa as compared to other bacteria: Re-
sults of a 13-year prospective cohort study. Antimicrob Agents 
Chemother 2017; 61(6). pii: e02671-16. DOI: 10.1128/AAC.02671-
16.
11. Tumbarello M, Repetto E, Trecarichi EM et al. Multidrug-resistant 
Pseudomonas aeruginosa bloodstream infections: risk factors 
and mortality. Epidemiol Infect 2011; 139(11):1740-1749. DOI: 
10.1017/S0950268810003055
12. Micek ST, Wunderink RG, Kollef MH et al. An international mul-
ticenter retrospective study of Pseudomonas aeruginosa nosoco-
mial pneumonia: impact of multidrug resistance. Crit Care 2015; 
19:219. DOI: 10.1186/s13054-015-0926-5
13. Tumbarello M, De Pascale G, Trecarichi EM et al. Clinical outcomes 
of Pseudomonas aeruginosa pneumonia in intensive care unit 
patients. Intensive Care Med 2013; 39(4):682-692. DOI: 10.1007/
s00134-013-2828-9
14. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, 
extensively drug-resistant and pandrug-resistant bacteria: an in-
ternational expert proposal for interim standard definitions for ac-
quired resistance. Clin Microbiol Infect 2012; 18(3):268-281. DOI: 
10.1111/j.1469-0691.2011.03570.x
15. Juan C, Zamorano L, Perez JL, Ge Y, Oliver A. Activity of a new 
antipseudomonal cephalosporin, CXA-101 (FR264205), against 
carbapenem-resistant and multidrug-resistant Pseudomonas 
aeruginosa clinical strains. Antimicrob Agents Chemother 2010; 
54(2):846-851. DOI: 10.1128/AAC.00834-09
16. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Anti-
microbial activity of ceftolozane/tazobactam tested against 
Pseudomonas aeruginosa and Enterobacteriaceae with various 
resistance patterns isolated in European hospitals (2011-2012). J 
Antimicrob Chemother 2014; 69(10):2713-2722. DOI: 10.1093/jac/
dku184
17. Nichols WW, de Jonge BL, Kazmierczak KM, Karlowsky JA, Sahm 
DF. In Vitro Susceptibility of Global Surveillance Isolates of Pseu-
domonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 
2014). Antimicrob Agents Chemother 2016; 60(8):4743-4749. DOI: 
10.1128/AAC.00220-16
18. Huband MD, Castanheira M, Flamm RK, Farrell DJ, Jones RN, Sader 
HS. In vitro activity of ceftazidime-avibactam against contempo-
rary Pseudomonas aeruginosa isolates from United States medical 
centers by Census region (2014). Antimicrob Agents Chemother 
2016; 60(4):2537-2541. DOI: 10.1128/AAC.03056-15
19. Canton R, Maiz L, Escribano A et al. Spanish consensus on the 
prevention and treatment of Pseudomonas aeruginosa bronchi-
al infections in cystic fibrosis patients. Arch Bronconeumol 2015; 
51(3):140-150. DOI: 10.1016/j.arbres.2014.09.021
20. Polverino E, Goeminne PC, McDonnell MJ et al. European Respira-
tory Society guidelines for the management of adult bronchiecta-
sis. Eur Respir J 2017; 50(3). DOI: 10.1183/13993003.50017-2017
21. Lister PD, Wolter DJ, Hanson ND. Antibacterial-Resistant Pseu-
meninges and the risk of encephalopathy (seizures) associated 
with elevated doses of β-lactams (cefepime, ceftazidime 
or imipenem) and to lesser extent with fluoroquinolones. 
Treatment can be 2 g/8 h iv meropenem or ceftazidime [232], 
associated or not (according to the strain susceptibility) 
with 400 mg/8 h iv ciprofloxacin. Among other potentially 
efficacious antibiotics, if the strain is susceptible,  they 
should be considered 16-24 g/day fosfomycin and intratecal 
or intraventricular administration [233,234] of 5-20 mg/day 
tobramycin, 30 mg/day amikacin or 10-20 mg/day colistin as 
colistimethate (1 mg of colistimethate = 12,500 UI) [235].  Up 
to now, no experience with the use of ceftolozane-tazobactam 
is available. 
Table 4 shows initial doses of antibiotics active against 
P. aeruginosa for severe infections.
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